Engineering *Saccharomyces cerevisiae* to produce plant benzylisoquinoline alkaloids

Jianing Han¹, Yinan Wu¹, Yilun Zhou¹, Sijin Li¹

¹ Robert Frederick Smith School of Chemical and Biomolecular Engineering, 230A Olin Hall, Cornell University, Ithaca, NY 14853, USA

Received: 4 March 2021 / Accepted: 29 June 2021 / Published online: 18 July 2021

**Abstract** Benzylisoquinoline alkaloids (BIAs) are a diverse family of plant natural products with extensive pharmacological properties, but the yield of BIAs from plant is limited. The understanding of BIA biosynthetic mechanism in plant and the development of synthetic biology enable the possibility to produce BIAs through microbial fermentation, as an alternative to agriculture-based supply chains. In this review, we discussed the engineering strategies to synthesize BIAs in *Saccharomyces cerevisiae* (yeast) and improve BIA production level, including heterologous pathway reconstruction, enzyme engineering, expression regulation, host engineering and fermentation engineering. We also highlight recent metabolic engineering advances in the production of BIAs in yeast.

**Keywords** Benzylisoquinoline alkaloids (BIAs), *Saccharomyces cerevisiae*, Synthetic biology, Metabolic engineering

**INTRODUCTION**

Benzylisoquinoline alkaloids (BIAs) are a family of plant natural products produced by *Ranunculales* plants, such as opium poppy (*Papaver somniferum*), California poppy (*Eschscholzia californica*), Japanese goldthread (*Coptis japonica*), and barberry (*Berberis wilsonae*) (Hagel and Facchini 2013). There are approximately 2500 different identified BIAs (Facchini and Luca 2008), many of which exhibit extensive pharmacological properties and have been used in traditional medicine for thousands of years. For example, morphine and codeine derived from opium poppy are potent analgesics (Aragon-Poce et al. 2002; Price et al. 1985). Berberine, the active compound of traditional Chinese medicine Huang Lian, is a widely used antimicrobial; it also exhibits anticancer potential by stabilizing human telomeric DNA (Guaman-Ortiz et al. 2014; Bessi et al. 2012) and antidiabetic potential by regulating glucose and lipid metabolism (Yin et al. 2008; Yin et al. 2002). Noscapine, a phthalideisoquinoline alkaloid derived from opium poppy, is a safe, nonnarcotic cough suppressant and has proven to possess anticancer properties (Dahlstrom et al. 1982; Landen et al. 2004; Mahmoudian and Rahimi-Moghaddam 2009; Chen et al. 2015). Chemical structures of these pharmaceutical BIAs are shown in Fig. 1.

The supply of medicinal BIAs largely relies on the farming of plants. For example, opium poppy is a major natural source of BIAs, including morphine, codeine, sanguinarine, noscapine and papaverine (Winzer et al. 2015). In 2019, approximately 240, 800 hectares of opium poppy were cultivated and produced 73 tons of pharmaceutical opioids (United Nations publication 2020). However, this supply chain based on agriculture could be costly in terms of land and water resource. It is also susceptible to environmental factors such as pests and climate. The fragile agriculture-based supply chain is also vulnerable to global uncertainties and crisis such as the ongoing COVID-19 pandemic.

The importance of BIAs and the vulnerable supply chain have prompted research into the BIA biosynthetic...
methylene (SAM)-dependent methyltransferases, namely norcoclaurine 6-O-methyltransferase (6OMT) (Morishige et al. 2000; Ounaroon et al. 2003), coallurine $N$-methyltransferase (CNMT) (Choi et al. 2001), and 3$'$-hydroxy-$N$-methylcoclaurine 4$'$-O-methyltransferase (4$'$OMT) (Morishige et al. 2000), together with one cytochrome P450 monooxygenase $N$-methylcoclaurine 3$'$-hydroxylase (NMCH) (Pauli and Kutchan 1998; Frick et al. 2007), catalyze the following steps converting (S)-norcoclaurine to (S)-reticuline.

(S)-reticuline is an important branch point in the BIA biosynthetic pathway. It can be converted to (R)-reticuline in opium poppy to produce morphine by a fusion enzyme DRS-DRR that contains a cytochrome P450 domain and a NADPH-dependent aldo-keto reductase domain. The discovery and identification of DRS-DRR was accomplished via mutant characterization (Winzer et al. 2015) or functional transcriptome analysis (Farrow et al. 2015; Galanie et al. 2015). (R)-reticuline is then converted to (7S)-salutaridinol 7-O-acetate by salutaridinol synthase (SalSyn) (Geisel et al. 2009), salutaridinol reductase (SalR) (Ziegler et al. 2006) and salutaridinol 7-O-acetyltransferase (SalAT) (Grothe et al. 2001). The reaction converting (7S)-salutaridinol 7-O-acetate to thebaine was considered to be spontaneous in the past. However, a recent study isolated and characterized another PR10 protein from opium poppy, namely thebaine synthase (THS), as the key enzyme that catalyzes the reaction (Chen et al. 2018). The final step that produces morphine from thebaine is catalyzed by thebaine 6-O-demethylase (T6ODM) (Hagel and Facchini 2010), codeine O-demethylase (CODM) (Hagel and Facchini 2010), codeinone reductase (COR), and neopine isomerase (NIS), which is the third PR10 protein involved in morphine pathway and was recently discovered via virus-induced gene silencing (VIGS) (Dastmalchi 2019a).

(S)-reticuline can also be converted to protoberberine-type BIAs and then lead to the synthesis of sanguinarine, noscapine, or berberine. Such biosynthetic routes start with the production of (S)-scoulerine catalyzed by berberine bridge enzyme (BBE), a FAD-linked oxidoreductase (Winkler et al. 2008). The downstream pathway converts (S)-scoulerine to sanguinarine via four cytochrome P450s, including chelanthifoline synthase (CFS) (Chávez et al. 2011), stylopine synthase (SPS) (Chávez et al. 2011), (S)-cis-$N$-methylstylojaponin 14-hydroxylase (MSH) (Beaudoin and Facchini 2013), protopine 6-hydroxylase (P6H) (Takemura et al. 2013), one methyltransferase, tetrahydroprotoberberine cis-$N$-methyltransferase (TNMT), and one FAD-linked oxidoreductase, dihydrobenzophenanthridine oxidase (D BOX) (Hagel et al. 2012). Another major downstream

machinery in plants. Recent advances in plant genomics, transcriptomics, proteomics and metabolomics have established the foundation that leads to the identification of plant enzymes and the cascaded reactions they catalyze, namely, biosynthetic pathways enabling BIAs (Dang et al. 2012). BIA biosynthetic pathway and enzymes involved in the pathway have been extensively reviewed (Dang et al. 2012; Beaudoin and Facchini 2014; Singh et al. 2019). Briefly, as shown in Fig. 1, the biosynthesis of all known BIAs start from two tyrosine derivatives, 4-hydroxyphenylacetaldehyde (4HPAA) and dopamine. 4-HPAA and dopamine undergo a PictetSpengler condensation to form (S)-norcoclaurine, the first committed intermediate in BIA synthesis. This reaction is catalyzed by norcoclaurine synthase (NCS), which belongs to the pathogenesis-related (PR)10/Bet v1 protein family (Samanani et al. 2004; Liscombe et al. 2005; Lee and Facchini 2010). Three $S$-Adenosyl

**Fig. 1** Representative biosynthetic pathway of BIAs in plant. Key metabolites and enzymes are shown. Block arrows indicate enzymes that have been identified and functionally characterized. Arrow outlines indicate subcellular localization associated with ER: Brown, ER membrane-bound; blue, ER lumen. Enzyme types are identified by colored circles: Blue, PR 10 protein; white, methyltransferase; brown, cytochrome P450; yellow, NADPH-dependent aldo-keto reductase; red, NADPH-dependent short-chain dehydrogenase/reductase; gray, acetyltransferase; pink, 2-OG/Fe (II)-dependent demethylase; purple, FAD-linked oxidoreductase; green, carboxylesterase. Background colors indicate BIA subgroups: Yellow, simple benzylisoquinoline type; purple, prophanine and morphinine type; pink, protoberberine type; blue, protopine and benzophenanthridine type; green, phthalidisoquinoline type; gray, aporphine type; brown, bisbenzylisoquinoline type. AT1 $1,13$-dihydroxy-$N$-methylcoclaurine 13-$O$-acetyltransferase; BBE berberine bridge enzyme; CAS canadine synthase; CFS chelanthifoline synthase; CNMT coclaurine $N$-methyltransferase; CODM codeine $O$-demethylase; COR codeinone reductase; CEX1 $3$-$O$-acetylperoxine carboxylesterase; CTS $O$-methyltransferase; DBOX dihydrobenzophenanthridine oxidase; DRS-DRR 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase; MSH $N$-methylstylojaponin 14-hydroxylase; N7OMT norreticuline 7-$O$-methyltransferase; NCS norcoclaurine synthase; NIS neopine isomerase; NMCH $N$-methylcoclaurine 3$'$-hydroxylase; NOS noscapine synthase; N4$'$MT narcotoline 4$'$-$O$-methyltransferase; P6H protopine 6-hydroxylase; RNMT reticuline $N$-methyltransferase; SalAT salutaridinol 7-$O$-acetyltransferase; SalSyn salutaridinol synthase; S9OMT scoulerine 9-$O$-methyltransferase; SPS stylopine synthase; STOX tetrahydroprotoberberine oxidase; T6ODM thebaine 6-$O$-demethylase; THS thebaine synthase; TNMT tetrahydroprotoberberine $N$-methyltransferase; 4$'$OMT 3$'$-hydroxy-$N$-methylcoclaurine 4$'$-O-methyltransferase; 6OMT norcoclaurine 6-$O$-methyltransferase; 4-HPAA 4-hydroxyphenylacetaldehyde
pathway starting from (S)-reticuline via (S)-scoulerine leads to the synthesis of berberine and noscapine. Comparative transcriptomics analysis between noscapine-producing and non-producing opium poppy variants has identified a 10-gene noscapine cluster in opium poppy chromosome (Winzer et al. 2012) including scoulerine 9-O-methyltransferase (SOMT) (Dang and Facchini 2012), canadine synthase (CAS, CYP719A) (Dang and Facchini 2014), N-methylcanadine 1-hydroxylase (CYP82Y1), 1-hydroxy-N-methylcanadine 13-O-hydroxyxylase (CYP82X2), 1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase (AT1), 1-hydroxy-13-O-acetyl-N-methylcanadine 8-hydroxylase (CYP82X1), 3-O-acetypapaveroxine carboxylesterase (CXE1), narcotoline-4'-O-methyltransferase (N4'OMT), and a short-chain dehydrogenase/reductase noscapine synthase (NOS). In particular, narcotoline-4'-O-methyltransferase (N4'OMT) is a heterodimer of two methyltransferase (Li and Smolke 2016). (S)-canadine, the product of SOMT and CAS can also be converted to berberine by a FAD-linked oxidoreductase, (S)-tetrahydroxyprotoberberine oxidase (STOX) (Amann et al. 1988; Gesell et al. 2011), or via a spontaneous reaction (Galiane and Smolke 2015).

Biosynthesis of aporphines, for example, magnoflorine, also starts from (S)-reticuline. In C. japonica, a cytochrome P450, corytuberine synthase (CTS, CYP80G2) catalyzes the intramolecular C-C phenol bond formation of (S)-reticuline, leading to corytuberine, and then CNMT catalyzes the conversion from corytuberine to magnoflorine (Ikezawa et al. 2008). While CNMT is a multi-functional enzyme that also catalyzes the N-methylation of coclaurine, a reticuline N-methyltransferase (RNMT) (Morris and Facchini 2016) was recently isolated from opium poppy root as a specific enzyme for the conversion of corytuberine to magnoflorine.

While (S)-reticuline is the central branch point of BIA biosynthetic pathway, metabolites upstream of (S)-reticuline can also serve as the branch point for other kinds of BIAs. For example, biosynthesis of papaverine starts from (S)-coclaurine via a partially characterized pathway with only a few enzymes identified. 4'OMT and norreticuline 7-O-methyltransferase (N7OMT) was proved to be involved in the synthetic pathway of tetrahydropapaverine (Pienkny et al. 2009), while a proposed 3'-hydroxylase and a proposed 3'OMT still remain uncharacterized. The conversion from tetrahydropapaverine to papaverine can be catalyzed by DBOX, but with only 43% efficiency (Hagel et al. 2012). A short-chain dehydrogenase/reductase, referred as DeHase, was recently discovered in opium poppy, which may be the putative specific enzyme for catalyzing this step, indicated by expression analysis and VIGS (Agarwal et al. 2020). Bisbenzylisoquinolines are another subgroup of BIAs. The synthesis of bisbenzylisoquinolines starts from the conversion from N-methylcoclaurine to berbamunine, catalyzed by berbamunine synthase (CYP80A1) (Kraus and Kutchan 1995). Berbamunine can be further converted to other bisbenzylisoquinolines, but the downstream pathway has not been identified yet.

The understanding of BIA biosynthetic pathways in BIA-producing plants such as opium poppy and the development of synthetic biology makes it feasible to produce BIAs in heterologous hosts, especially in microorganisms. Compared with sourcing BIAs from cultured plants, fermentation in a tractable microbial host such as Saccharomyces cerevisiae or Escherichia coli is more rapid, cost-effective, efficient (Rathbone and Bruce 2002) and environmentally friendly (Cordell 2011). However, the complexity of plant BIA pathway hinders its reconstruction in a bacterial host such as E. coli. BIA biosynthesis involves multiple membrane-bound cytochrome P450 enzymes, and several other enzymes that are also associated with endoplasmic reticulum (ER) lumen (Hagel and Facchini 2012), such as NCS, BBE and DBOX (Fig. 1). For example, to produce thebaine in E. coli, the reaction catalyzed by DRS-DRR has to be circumvented because of the low activity of this fusion enzyme in bacterium (Nakagawa et al. 2016). Instead, S. cerevisiae (baker’s yeast), as a unicellular eukaryotic model microorganism, can provide the endomembrane system for the functional expression of membrane-bound plant enzymes. The well-studied yeast metabolism also makes it a tractable host for metabolic engineering. The development of synthetic biology provides a variety of genetic tools and elements to reconstruct heterologous pathways and enables dynamically regulation of the expression of diverse proteins respectively (Redden and Alper 2015). Finally, reconstructing de novo BIA biosynthetic pathways in yeast enables the production of novel BIA derivatives. The broad substrate specificity of some enzymes in BIA pathway allows us to produce BIA derivatives by feeding modified simple molecules such as tyrosine derivatives to yield new structures and concomitant bioactivities. In this review, we discuss the engineering strategies to reconstruct BIA synthetic pathway in yeast and to improve the production of BIAs, as well as major achievements in the production of diverse BIAs in yeast.
STRATEGIES FOR PRODUCING BIAS IN YEAST

Non-native pathway construction

Despite the research progress in understanding the BIA biosynthetic pathway, several enzymes catalyzing certain reactions remain unidentified. A strategy to fill in these gaps is to introduce non-native enzymes from other organisms that can catalyze the same reactions, especially those catalyzing the upstream reactions leading to dopamine and 4-HPAA synthesis that are common in different organisms. For example, the production of dopamine that enables de novo BIA biosynthetic pathway reconstruction in yeast has remained challenging for long, as the enzymes for dopamine synthesis in BIA-producing plant have not been fully elucidated yet (Singh et al. 2019). Instead, a bacterial dihydroxyphenylalanine (DOPA) decarboxylase (DoDC) from *Pseudomonas Putida* (Koyanagi 2012) was reported to convert DOPA to dopamine (Fig. 2A). Engineered yeast expressing PpDoDC can produce dopamine and the downstream product norcoclaurine with a titer of 49 µg/L, when fed with 2 mM DOPA in the cultural medium (Trenchard et al. 2015). Then the next step is to find an enzyme (tyrosine 3-hydroxylase, TyrH) that can catalyze the reaction from tyrosine to DOPA in yeast. Two different approaches were employed here (Fig. 2A). An enzyme-coupled biosensor was developed to screen for heterologous tyrosine hydroxylase that are active in yeast (DeLoache et al. 2015). The DOPA produced by the candidate TyrH was converted by a plant DOPA dioxygenase to betaxanthin in yeast. Betaxanthin is a yellow pigment that is produced by plants in Caryophyllales in nature, the accumulation of which leads to yeast colorimetric change and corresponding TyrH screening (DeLoache et al. 2015). With this biosensor, a tyrosine hydroxylase (CYP76AD1) from *Beta vulgaris* (sugar beets) was identified to possess high activity in yeast and produced 1.3 mg/L DOPA (DeLoache et al. 2015). Reconstruction of the downstream pathway led to the de novo production of (S)-reticuline with a titer of 80.6 µg/L (DeLoache et al. 2015). Instead of plant TyrH, another alternative candidate is a mammalian tyrosine hydroxylase TyrH.

---

**Fig. 2** Representative strategies and examples to produce BIAs in yeast. **A** Reconstruction of dopamine biosynthetic pathway via non-native enzymes. Orange arrow, bacterial enzyme; purple arrow, mammalian enzyme; green arrow, plant enzyme. DOPA, dihydroxyphenylalanine; PpDoDC, DOPA decarboxylase from *Pseudomonas Putida*; RnTyrH, tyrosine 3-hydroxylase from *Rattus norvegicus* (Brown rat); BvCYP76AD1, tyrosine 3-hydroxylase from *Beta vulgaris* (sugar beets). **B** Schema of protein engineering on N-terminal signal peptide to guide the correct localization and enhance the activity of plant cytochrome P450 enzymes. **C** Engineering of yeast endogenous pathway to produce 4-HPAA. Red outlines indicate engineered enzymes. *Aro10p* phenylpyruvate decarboxylase; *Aro1p* pentafunctional arom enzyme; *Aro2p* bifunctional chorismate synthase and flavin reductase; *Aro4p* DAHP synthase with feedback inhibition-resistant mutation Q166K; *Aro7p* chorismate mutase with feedback inhibition-resistant T266I; *Aro9p* aromatic aminotransferase I; *Aro9p* aromatic aminotransferase II; *E4P* erythrose-4-phosphate; *PEP* phosphoenolpyruvate; 4-HPAA 4-hydroxyphenylacetaldehyde.
from *Rattus norvegicus* (Brown rat) (Trenchard et al. 2015). RnTyrH exhibits higher substrate and product specificity compared with other kinds of tyrosine hydroxylase from plants or bacteria. However, it relies on the electron carrier tetrahydrobiopterin (BH4) that is absent in wild-type yeast (Trenchard et al. 2015). Therefore, four additional mammalian enzymes were introduced into engineered yeast to enable BH4 synthesis pathway (Trenchard et al. 2015). Eventually, 19.2 µg/L (S)-reticuline titer was achieved by the additional introduction of DODC and other five down-stream enzymes (Trenchard et al. 2015). These yeast strains with non-native dopamine biosynthetic pathways provide dopamine as the essential building block molecules for diverse BIA synthesis.

**Enzyme engineering**

Protein directed evolution is a widely used strategy to increase an enzyme’s catalytic activity, substrate specificity, or to decrease product feedback inhibition. For example, in addition to the tyrosine hydroxylase activity, wild-type CYP76AD1 also exhibits DOPA oxidase activity (Hatlestad et al. 2012), which is undesirable for BIA production. From an enzyme variant library containing approximately 200,000 members, researchers obtained a W13L F309L variant of CYP76AD1 associated with 2.8-fold higher DOPA production and correspondingly decreased DOPA oxidase activity (DeLoache et al. 2015). The mammalian TyrH was also engineered via site-directed mutagenesis with W166Y R37E R38E mutations to relieve the product feedback inhibition and increase the noscapine titer by ninefold over the strain with wild-type TyrH enzyme (Trenchard et al. 2015).

The subcellular localization of enzymes is another important factor that can influence the function of enzymes. A variety of cytochrome P450 enzymes are involved in BIA synthetic pathway, all of which need to localize to the endoplasmic reticulum (ER) membrane and to face the cytosolic surface of ER membrane correctly. N-terminal signal peptide that guides the correct localization of ER-bound protein is critical in this process, and therefore becomes the key target in enzyme localization engineering (Fig. 2B). For example, in morphine biosynthetic pathway, salutaridine synthase (Sal-Syn) is a key enzyme that used to show low activity in yeast, as a number of nascent proteins were incorrectly localized on ER membrane surface facing the lumen (Galanie et al. 2015). Replacing the N-terminal signal peptide of SalSyn with another cytochrome P450 signal peptide led to a chimeric SalSyn that could be anchored on ER membrane correctly and improved the production of salutaridine by sixfold (Galanie et al. 2015).

Meanwhile, the function of some other enzymes that are localized into ER in plant does not rely on ER in microorganisms. For example, the localization of NCS in ER lumen may even have a negative effect on its catalytic efficiency in yeast. Hence, a noscapine-producing yeast strain that expressed an NCS variant with the first 24 amino acids deleted increased the end-product noscapine production by eightfold compared with the strain with wild-type NCS (Li et al. 2018).

**Regulation of gene expression**

Expression of heterologous enzymes may bring extra expression burden to the engineered yeast cells, especially for those ER membrane-bound cytochrome P450 enzymes. Overexpression of cytochrome P450 enzymes can trigger a stress response in yeast that leads to abnormal proliferation of ER (Sandig et al. 1999). As a result, the expression of these enzymes needs to be tuned to yield optimal productivity. In yeast, a variety of promoters have been characterized as standard genetic elements to drive gene expression at different levels. For example, five different yeast promoters (P*GPD*, P*Tef1*, P*Pgi1*, P*Tpi1*, and P*HXT7*) were used to drive the expression of cheilanthifoline synthase (CFS) where P*Pgi1* provided a tenfold improvement in cheilanthifoline production compared to the other promoters (Trenchard and Smolke 2015). The process of tuning expression level can become easier with the use of inducible promoters, such like the GAL promoters that can be activated by galactose. The GAL promoters have been used to regulate the expression of three methyltransferases (6OMT, 4’OMT and CNMT) in engineered yeast. With these tunable strains, researchers characterized the relationship between galactose concentration, enzyme expression levels and reticuline production, and thus determined the optimal expression level of these enzymes (Hawkins and Smolke 2008). Gene copy number is another factor that can influence the expression level. For example, 4’OMT has been long believed to be the bottleneck of the conversion from (S)-norcoclarine to (S)-reticuline. It has been recently proven by the integration of an additional copy of 4’OMT that resulted in a 45% improvement in (S)-reticuline titer (Pyne et al. 2020). Moreover, the ratio of gene copy number is also important. In the reconstruction of morphine pathway in yeast, the highest morphine production was achieved when the copy number of three genes encoding enzymes (T6ODM, COR and CODM) was 2:1:3, increasing twofold compared with the original strain with enzyme copy number in 1:1:1 ratio (Thodey et al. 2014).
Host engineering

The endogenous pathways in yeast play an important role in BIA synthesis. The production of 4-HPAA in yeast is closely related to the central metabolism. In yeast, 4-HPAA is an endogenous metabolite that can be synthesized from two central metabolites, phosphoenolpyruvic acid (PEP) in glycolysis and erythrose-4-phosphate (E4P) in pentose phosphate pathway (Fig. 2C). Incorporation of Q166K feedback inhibition-resistant mutant of 3-deoxy-arabino-heptulonate-7-phosphate synthase (DHAP synthase, Aro4) (Fukuda et al. 1992) resulted in 14-fold increase in norcoclaurine production (Trenchard et al. 2015). Deletion of the endogenous zwf1 gene encoding glucose-6-phosphate and upregulation of TKL1 gene encoding transketolase further increased norcoclaurine production by 60-fold (Trenchard et al. 2015), as these modifications directed the flux in pentose phosphate pathway to favor E4P. However, the deletion of zwf1 decreased the production of downstream compound such as noscapine (Li et al. 2018). One possible reason is that zwf1 deletion decreased NADPH level, which is an important cofactor for cytochrome P450 enzymes (Li et al. 2018). Additionally, 4-HPAA can be rapidly converted to alcohols via the Ehrlich pathway. Seven genes (ari1, adh6, ypr1, ydr541c, aad3, gre2 and hfd1) are involved in the consumption of 4-HPAA; knocking out of these genes increased norcoclaurine and (S)-reticuline production in yeast (Pyne et al. 2020).

Fermentation engineering

Parameters in fermentation such as pH and temperature, have a remarkable impact in the production of BIA. pH can significantly affect the activity of yeast in microbial fermentation and thus influence the production of BIA. For example, in the production of canadine, maintaining higher pH conditions at 5–5.7 improved the titer by approximately threefold compared with the unbuffered media at pH 3.5–5.7 (Galanie and Smolke 2015). Temperature is another key factor in BIA production due to the enhanced activity and stability of many plant enzymes at lower temperature. In a protoberberine-producing strain, stylopine production increased by 3.4-fold when the strain was grown at 25 °C compared to 30 °C. However, the effect of temperature does not always take place on all enzymes. For example, in a berberine-producing strain, temperature showed no influence on the production of berberine and canadine (Galanie and Smolke 2015).

The production of BIAs can also be influenced by the primary carbon source in the cultural medium. Galactose was shown to have a positive effect on the production of stylopine (Trenchard and Smolke 2015), canadine and berberine (Galanie and Smolke 2015), possibly due to its regulatory effect on the expression of several yeast endogenous pathways. In noscapine production, trehalose was found to be the best source, increasing the titer by 50-fold (Li et al. 2018).

Additionally, sufficient cofactor level is essential to enzyme functions. For example, as mentioned above, BH4 synthesis pathway was introduced into yeast when mammalian TyrH was selected for DOPA production. Furthermore, adding 2 mM ascorbic acid to media can increase DOPA production by 1.5-fold as ascorbic acid prevents the oxidation of BH4 and increase the activity of TyrH (Trenchard et al. 2015). For morphine production, two demethylases, T6ODM and CDM, require 2-oxoglutarate as the cofactor. In the production of semisynthetic opioid drug hydrocodone, 50 mM 2-oxoglutarate was added to media to support T6ODM activity (Galanie et al. 2015).

APPLICATIONS

High-level production of (S)-reticuline in yeast

As most BIAs are derived from (S)-reticuline, a yeast platform with high level of (S)-reticuline production is essential to produce other downstream BIAs. The first yeast strain for (S)-reticuline production was reported in 2008 (Table 1) (Hawkins and Smolke 2008), with the integration of 6OMT, CNMT and 4’OMT from P. somniferum, in which norlaudanosoline (NLDS) was used as the substrate. Reconstruction of non-native dopamine synthetic pathway in yeast has overcome the obstacle of the de novo production of (S)-reticuline. In 2015, as is mentioned above, heterologous expression of plant TyrH (DeLoache et al. 2015) or mammalian TyrH (Trenchard et al. 2015) lead to 80.6 or 19.2 µg/L of de novo (S)-reticuline production from tyrosine, respectively (Table 1). However, the production is still not comparable with that in bacteria like E. coli, which has reached 46 mg/L in 2011 (Nakagawa et al. 2011) and 160 mg/L in 2018 (Matsumura et al. 2018), yet bacteria are not suitable hosts for the downstream BIA pathways due to the lack of membrane-bound organelles for the functional expression of cytochrome P450 enzymes. A great breakthrough that tremendously enhanced (S)-reticuline production in yeast was achieved in 2020. The production of (S)-reticuline in yeast reached 4.6 g/L (Table 1), by introducing a new TryH ortholog (CYP76ADS5), adjusting the gene copy number, and
 deleting seven host oxidoreductase that competitively consume precursor 4-HPAA (Pyne et al. 2020).

### Production of morphinan alkaloids in yeast

Among the reconstruction of downstream BIA pathways, the branched pathway towards morphinan alkaloids is the most attracting due to the high pharmaceutical value of products like morphine and codeine and semisynthetic opioids like oxycodone, hydrocodone, and hydromorphone. Before the identification of the enzyme for the synthesis of (R)-reticuline from (S)-reticuline, it was impossible to engineer a recombinant host for the de novo production of morphinan alkaloids. Using (R)-norlaudanosoline as the substrate, (R)-reticuline was produced via 6OMT, CNMT and 4OMT with the titer of about 150 mg/L, and further salutaridine was produced for the first time with the titer of approximately 20 mg/L (Hawkins and Smolke 2008), which is the first morphinan alkaloid produced in yeast. In 2014, high-value morphinan alkaloids including codeine (7.7 mg/L), morphine (4.7 mg/L), hydrocodone (51 mg/L) and oxycodone (70 mg/L) were successfully produced from thebaine in yeast (Table 1) (Thodey et al. 2014). The synthetic pathway of thebaine from (R)-reticuline was subsequently reconstructed in yeast, with a thebaine titer of 0.31 mg/L (Table 1) (Fossati et al. 2015). Finally, with the identification of DRS-DRR that catalyzes the conversion from (S)-reticuline to (R)-reticuline, the de novo synthesis of morphinan alkaloids was achieved in 2015, with the production of 6.4 g/L thebaine and 0.3 g/L hydrocodone (Table 1) (Galanie et al. 2015). The engineered yeast strains were further optimized based on new discovery of synthetic mechanism in plant. For example, in 2018, thebaine synthase (THS), which was newly discovered to catalyze the formation of thebaine from 7-(S)-salutaridinol 7-O-acetate, was incorporated in engineered yeast and increased thebaine production by 24-fold compared with the strain that relied on

### Table 1 Major advances in BIA production in yeast

| Substrate | Product         | Titer     | Comments                                           | Ref          |
|-----------|-----------------|-----------|---------------------------------------------------|--------------|
| (R,S)-NLDS| (S)-reticuline  | 150 mg/L  | First synthesis of BIAs in yeast                  | Hawkins and Smolke (2008) |
|           | Salutaridine    | 20 mg/L   | Intermediate to morphine                          |              |
|           | Canadine        | 30 mg/L   | Intermediate to berberine and noscapine           |              |
|           |                 |           | Titers in this article are estimated based on percentage substrate conversion |              |
| De novo   | (S)-reticuline  | 80.6 μg/L | First de novo synthesis of reticuline in yeast with plant TyrH | DeLoache et al. (2015) |
| De novo   | (S)-reticuline  | 19.2 μg/L | De novo synthesis of reticuline in yeast with mammalian TyrH | Trenchard et al. (2015) |
| De novo   | (S)-reticuline  | 4.6 g/L   | Highest production of reticuline in yeast         | Pyne et al. (2020) |
| Thebaine  | Codeine         | 7.7 mg/L  |                                                    | Thodey et al. (2014) |
|           | Morphine        | 4.7 mg/L  |                                                    |              |
|           | Hydrocodone     | 51 mg/L   |                                                    |              |
|           | Oxycodone       | 70 mg/L   |                                                    |              |
| (R)-reticuline | Thebaine     | 0.31 mg/L |                                                    | Fossati et al. (2015) |
| De novo   | Thebaine        | 6.4 μg/L  | DRS-DRR was identified to catalyze the key step from (S)- to (R)-reticuline | Galanie et al. (2015) |
|           | Hydrocodone     | 0.3 μg/L  |                                                    |              |
| (R,S)-NLDS| Thebaine        | 0.7 mg/L  | Improved titer by incorporating THS                | Chen et al. (2018) |
| (R,S)-NLDS| Canadine        | 1.8 mg/L  |                                                    | Galanie and Smolke (2015) |
|           | Berberine       | 6.5 μg/L  |                                                    | Li and Smolke (2016) |
| (R,S)-NLDS| Noscapine       | 0.68 mg/L |                                                    | Li et al. (2018) |
| De novo   | Noscapine       | 2.2 mg/L  |                                                    | Trenchard and Smolke (2015) |
| (R,S)-NLDS| Sanguinarine    | 80 μg/L   |                                                    |              |
| Dopamine  | Magnoflorine    | 7.25 mg/L | Coculture with reticuline-producing E. coli       | Minami et al. (2008) |

NLDS norlaudanosoline; THS thebaine synthase; TyrH tyrosine 3-hydroxylase
spontaneous reaction for thebaine formation (Table 1) (Chen et al. 2018).

**Production of berberine, noscapine, sanguinarine, and magnoflorine in yeast**

Berberine, noscapine and sanguinarine are three representative pharmaceutical BIAs in addition to morphinan alkaloids. In 2008, based on the first (S)-reticuline-producing yeast, canadine, as the important precursor of berberine and noscapine, was produced in yeast (Hawkins and Smolke 2008). The strain was optimized by enzyme variant screening and genetic copy number variation, leading to a 1.8 mg/L canadine titer and 6.5 µg/L berberine production (Table 1) (Galanie and Smolke 2015). Noscapine synthetic pathway from norlaudanosoline was reconstructed in yeast in 2016 (Li and Smolke 2016), and optimized in 2018 (Table 1) (Li et al. 2018). The yeast strain harboring complete de novo noscapine synthetic pathway reached 2.2 mg/L titer of noscapine production (Li et al. 2018). Moreover, sanguinarine synthetic pathway was reconstructed and engineered in yeast, producing 80 µg/L sanguinarine (Table 1) (Trenchard and Smolke 2015). Although the sanguinarine titer is far below the need for commercial uses, the reconstruction of sanguinarine synthetic pathway provided valuable experiences and engineering strategies for the functional expression of multiple plant cytochrome P450 enzymes, as there are four cytochrome P450 enzymes involved in this pathway. Heterologous production of magnoflorine was achieved in the consortium fermentation of engineered E. coli and yeast: Engineered E. coli harboring a 5-gene pathway including monoamine oxidase (MAO), NCS, 6OMT, CNMT, and 4’OMT, provides reticuline to an engineered yeast that co-expressed CTS and CNMT. Engineered E. coli can efficiently produce (S)-reticuline from dopamine but lack the intercellular membrane structure to support the functional expression of cytochrome P450 enzymes in the downstream pathway. The co-culture system combines the advantages of higher reticuline production in E. coli and functional expression of CTS in yeast, and resulted in a titer of 7.2 mg/L (Minami et al. 2008).

**Production of novel BIA derivatives**

One of the goals of synthetic biology is to expand the diversity of natural products by engineering chemical modifications and structural scaffolds that have not ever existed in nature (Smanski et al. 2016). Owing to the broad substrate specificity of enzymes, engineered yeast is able to convert modified simple molecules, such as tyrosine derivatives, to novel BIA derivatives. Among the chemical modifications, halogenation of BIAs received the most attention. Halogens (fluorine, chlorine, bromine, and iodine) are highly prevalent in licensed drugs, and their benefits on pharmacokinetic properties have been thoroughly reviewed (Fejzagic’ et al. 2019; Bradley et al. 2020). In engineered yeast, 8-fluororeticuline and 8-chlororeticuline were produced when feeding 3-fluoro-tyrosine and 3-chloro-tyrosine, respectively, and 8-iodo-(S)-N-methylcoclaurine was produced when feeding 3-iodo-tyrosine (Li et al. 2018). The diversity of BIA structural scaffold can also be expanded by feeding exogenous amino acid analogs, due to the promiscuity of NCS. Sulfur-containing isoquinoline scaffold was formed in yeast when feeding methionine (Pyne et al. 2020). The production of ethyl-, propyl-, butyl-, and pentyl-substituted isoquinoline scaffolds in yeast were also achieved by feeding 2-aminobutyrate, norvaline, norleucine, and 2-aminoheptanoic acid, respectively, and these novel isoquinoline scaffolds can be further methylated by 6OMT and CNMT (Pyne et al. 2020). The biosynthesis of these novel BIA derivatives with various chemical modifications and structural scaffolds can dramatically broaden the diversity of BIAs for human to screen new drugs with novel pharmaceutical properties.

**CONCLUSION AND FUTURE PERSPECTIVE**

With the rapid development of synthetic biology, yeast has been engineered as a versatile microbial factory to produce a variety of high-value BIAs (e.g., morphine, codeine, berberine, and noscapine), which evinces profound potential to replace the traditional agriculture-based supply chain. In this review, we focus on the reconstruction, optimization, and engineering of BIA biosynthetic pathways that have been elucidated. Regarding the start-of-the-art strategies and progress identifying unknown pathways or missing steps in plant BIA metabolism (e.g., the missing enzymes in bisbenzylisoquinoline and papaverine synthesis), we refer the readers to a number of reviews (Dang et al. 2012; Beaudoin and Facchini 2014; Singh et al. 2019) outlining the discovery and characterization of BIA metabolism in plant.

Throughout this review, we have highlighted the synthetic biology strategies that have been leveraged in yeast to reconstruct the BIA biosynthetic pathway, to optimize the production, and to synthesize diverse unnatural BIA derivatives. However, great efforts are still needed both at laboratory and at industrial scale to achieve efficient and/or profitable biomanufacturing, levels, host backgrounds, and fermentation conditions.
However, for commercial production, further engineering efforts are still required to meet the minimal titer (~5 g/L) for yeast production of BIAs to be competitive with poppy farming (Galanie et al. 2015). Although the recent highest titer to date has reached 4.6 g/L for (S)-reticuline (Pyne et al. 2020), high-level production of downstream pharmaceutical BIAs still remains challenging for future work.

Functional expression of plant enzymes in yeast remains a bottleneck in BIA biosynthetic pathway reconstruction, even if the corresponding genes and enzymes have been identified and characterized in planta (Beaudoin and Facchini 2014; Singh et al. 2019). This gap hindering successful BIA pathway reconstruction relates back with the intrinsic structural and functional differences between plant and yeast cells. Lack of plant-specific organelles or space in yeast (e.g., chloroplasts and plant cell apoplast) might lead to an unfavorable chemical environment where the recombinant enzymes are inactive or less active. We anticipate that relocalization of plant enzymes into an appropriate yeast organelle can tackle this challenge: For example, although plant NCS is localized in ER lumen, engineered NCS that is localized in yeast cytosol increased BIA titer (Li et al. 2018), probably due to the enhanced transportation of metabolites. Intriguingly, a very recent study further revealed that high-level expression of cytosolic NCS is also toxic to yeast, and managed to enhance the BIA titer by relocalizing the recombinant NCS into peroxisome (Grewal et al. 2021). Therefore, protein engineering for the correct localization of plant enzymes in yeast is important to improve their catalytic activity and to increase the titer of BIAs.

Furthermore, we anticipate that novel strategies to optimize the multi-enzyme pathway in a synchronized manner are key to enhance the production of BIAs toward scalable biomanufacturing. In addition to the metabolic engineering and genome editing approaches that optimize target BIA production in a unicellular environment, co-culture of multiple types of cells, or consortia fermentation, shows the potential of addressing the expression burden in the long, complex BIA biosynthetic processes. Lower metabolic burden may increase the substrate and energy utilization in individual strains and therefore increase the overall efficiency of the co-culture system. It has become a widely used strategy in biotechnology, especially when producing complex chemicals from simple small molecules, which has been extensively reviewed recently (Diender et al. 2021). Intercellular transportation is always an important concern in co-culture system. The recent discovery of a BIA-specific transporter family (Dastmalchi 2019b) may broaden the application of co-culture system in BIA synthesis.

Another exciting application of microbial biomanufacturing is the biosynthesis of "unnatural" BIAs that have tailormade modifications towards enhanced pharmaceutical activities, which is difficult to pursue using traditional methods. While modified substrate fed into BIA-producing yeast (e.g., tyrosine derivatives) may lead to novel BIA derivative production, the BIA biosynthetic pathways that are composed of enzymes similar or identical to the wild-type plant enzymes usually do not exhibit high promiscuity or efficiency in unnatural BIA derivative synthesis. Aiming at a more flexible and efficient microbial platform, it is essential to employ protein engineering methods to create engineered enzymes that have higher promiscuity and efficiency for BIA derivatives (e.g., halogenated noscapines) synthesis in yeast. This dilemma between substrate promiscuity and catalytic efficiency poses a new challenge to protein engineering, as low substrate specificity of an enzyme usually reduces the production of desired compound due to the competition of multiple substrates. De novo rational design and structural identification of the enzymes in BIA metabolism will be a promising approach to develop such tailormade enzymes for novel BIA derivative synthesis. Discovery and engineering of halogenases may provide an alternative way to produce BIA analogous by modifying BIAs directly. Although only a small number of halogenases were characterized and with limited substrate range, enzyme engineering efforts to exploit the substrate promiscuity (Brown and O’Connor 2015) based on the understanding of their mechanism will make it possible to incorporate them in the BIA synthetic pathways.

Acknowledgements This work was supported by the National Institutes of Health—National Institute on Deafness and Other Communication Disorders (grant to S.L., R21DC019206).

Funding J.H. is supported by the National Institutes of Health—National Institute on Deafness and Other Communication Disorders (grant to S.L., R21DC019206).

Availability of data and material Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest All authors declare that they have no conflict of interest.

Ethics approval Not applicable.

Consent to participate Not applicable.
catalyzes an intramolecular C-C phenol coupling of (S)-reticuline in magnoflorine biosynthesis, from cultured *Coptis japonica*. J Biol Chem 283:8810–8821

Koyanagi T et al (2012) Eukaryotic-type aromatic amino acid decarboxylase from the root colonizer *Pseudomonas putida* is highly specific for 3, 4-dihydroxyphenyl-L-alanine, an allelochemical in the rhizosphere. Microbiology 158:2965–2974

Kraus PF, Kutchan TM (1995) Molecular cloning and heterologous expression of a cDNA encoding berbamine synthase, a C-O phenol-coupling cytochrome P450 from the higher plant *Berberis stolonifera*. Proc Natl Acad Sci 92:2071–2075

Landen JW et al (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 10:5187–5201

Lee E-J, Facchini P (2010) Norcoclaurine synthase is a member of a review. Recent Pat Anticancer Drug Discov 4:92–97

Matsumura E et al (2018) Microbial production of novel sulphated alkaloids for drug discovery. Sci Rep 8:1–10

Minami H et al (2008) Microbial production of plant benzylisoquinoline alkaloids. Proc Natl Acad Sci 105:7393–7398

Morishige T, Tsujita T, Yamada Y, Sato F (2000) Molecular characterization of the S-adenosyl-L-methionine: 3’-hydroxyn-N-methylcoclaurine 4’-O-methyltransferase involved in isoquinoline alkaloid biosynthesis in *Coptis japonica*. J Biol Chem 275:23398–23405

Morris JS, Facchini PJ (2016) Isolation and characterization of reticuline N-methyltransferase involved in biosynthesis of the aporphine alkaloid magnoflorine in opium poppy. J Biol Chem 291:23416–23427

Nakagawa A et al (2011) A bacterial platform for fermentative production of plant alkaloids. Nat Commun 2:1–9

Nakagawa A et al (2016) Total biosynthesis of opiates by stepwise fermentation using engineered *Escherichia coli*. Nat Commun 7:1–8

Ounaroon A, Decker G, Schmidt J, Lottspeak F, Kutchan TM (2003) *(R, S)-Reticuline 7-O-methyltransferase and *(R, S)-norcoclaurine 6-O-methyltransferase of *Papaver somniferum*—cDNA cloning and characterization of methyl transfer enzymes of alkaloid biosynthesis in opium poppy. Plant J 36:808–819

Pauli HH, Kutchan TM (1998) Molecular cloning and functional heterologous expression of two alleles encoding *(S)-N-methylcoclaurine 3’-hydroxylase (CYP80B1), a new methyl jasmonate-inducible cytochrome P-450-dependent mono-oxygenase of benzylisoquinoline alkaloid biosynthesis. Plant J 13:793–801

Pienkny S, Brandt W, Schmidt J, Kramell R, Ziegler J (2009) Functional characterization of a novel benzylisoquinoline O-methyltransferase suggests its involvement in papavereine biosynthesis in opium poppy (*Papaver somniferum* L). Plant J 60:56–67

Price DD, Von der Gruen A, Miller J, Rafii A, Price C (1985) A psychophysical analysis of morphine analgesia. Pain 22:261–269

Pyne ME et al (2020) A yeast platform for high-level synthesis of tetrahydrosquamine alkaloids. Nat Commun 11:1–10

Rathbone DA, Bruce NC (2002) Microbial transformation of alkaloids. Curr Opin Microbiol 5:274–281

Redden H, Alper HS (2015) The development and characterization of synthetic minimal yeast promoters. Nat Commun 6:1–9

Samanani N, Liscombe DK, Facchini PJ (2004) Molecular cloning and characterization of norcoclaurine synthase, an enzyme catalyzing the first committed step in benzylisoquinoline alkaloid biosynthesis. Plant J 40:302–313

Sandig G et al (1999) Regulation of endoplasmic reticulum biogenesis in response to cytochrome P450 overproduction. Drug Metab Rev 31:393–410

Singh A, Menéndez-Perdomo IM, Facchini PJ (2019) Benzylisoquinoline alkaloid biosynthesis in opium poppy: an update. Phytochemistry 184:1457–1482

Smanski MJ et al (2016) Synthetic biology to access and expand nature’s chemical diversity. Nat Rev Microbiol 14:135

Takemura T, Ikezawa N, Iwasa K, Sato F (2013) Molecular cloning and characterization of a cytochrome P450 in sanguinarine biosynthesis from *Eschscholzia californica* cells. Phytochemistry 91:100–108

Thodey K, Galanie S, Smolke CD (2014) A microbial biomanufacturing platform for natural and semisynthetic opioids. Nat Chem Biol 10:837–844

Trenchard IJ, Smolke CD (2015) Engineering strategies for the fermentative production of plant alkaloids in yeast. Metab Eng 30:96–104

Trenchard IJ, Siddiqui MS, Thodey K, Smolke CD (2015) *De novo* production of the key branch point benzylisoquinoline alkaloid reticuline in yeast. Metab Eng 31:74–83

United Nations publication (2020) *World Drug Report 2020*

Winkler A et al (2008) A concerted mechanism for berberine bridge enzyme. Nat Chem Biol 4:739–741

Winzer T et al (2012) A *Papaver somniferum* 10-gene cluster for synthesis of the anticanccer alkaloid noscapine. Science 336:1704–1708

Winzer T et al (2015) Morphinan biosynthesis in opium poppy requires a P450-oxidoreductase fusion protein. Science 349:309–312

Yin J et al (2002) Effects of berberine on glucose metabolism *in vitro*. Metab Exp 51:1439–1443

Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717

Ziegler J et al (2006) Comparative transcript and alkaloid profiling in *Papaver* species identifies a short chain dehydrogenase/ reductase involved in morphine biosynthesis. Plant J 48:177–192